# OnCo record nct02864992 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02864992/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02864992", "NCT02864992" ;
  schema:name "VISION (tepotinib)"@en ;
  schema:alternateName "VISION"@en, "MS200095-0022"@en, "Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)"@en ;
  schema:description "VISION showed that a once-daily MET tablet shrank about half of advanced lung cancers driven by a MET exon 14 skipping mutation, whether the mutation was found in blood or in tumour tissue, which led to tepotinib's approvals in Japan, the United States and Europe."@en ;
  schema:url <https://onco.cc/trials/nct02864992/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02864992>, <https://doi.org/10.1056/NEJMoa2004407> ;
  onco:status "positive" ;
  onco:tag "pipeline", "issue-92" ;
  onco:phase "2" ;
  schema:startDate "2016-09-13" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/tepotinib/> ;
  onco:companies <https://onco.cc/companies/merck-kgaa/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-vision-tepotinib-paik-nejm-2020/>, <https://onco.cc/key-papers/paper-nct02864992-jama-oncol-2023-update/> .